Β-blockers: A new therapy in congestive heart failure

American Journal of Critical Care

Volumn 10, Issue 6, 2001, Pages 417-429

  Meghani, Salimah H ^a   Becker, Deborah ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC SYSTEM; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN; MORTALITY; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CONTROLLED CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; PATIENT EDUCATION; PRACTICE GUIDELINES; SYMPATHETIC NERVOUS SYSTEM;

EID: 0035513637     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2001.10.6.417     Document Type: Article

References (33)

1. Coodley E. Newer drug therapy for congestive heart failure. Arch Intern Med. 1999;159:1177-1183.
2. Tavazzi L. Epidemiological burden of heart failure. Heart. 1998;79(suppl 2):6S-9S.
3. Eichhorn EJ. Restoring function in failing hearts: the effects of beta blockers. Am J Med. 1998;104:163-169.
4. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-1435.
5. White CM. Catecholamines and their blockade in congestive heart failure. Am J Health Syst Pharm. 1998;55:676-682.
6. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation. 1999;99:786-792.
7. Pepper GS, Lee RW. Sympathetic activation in heart failure and its treatment with beta-blockade. Arch Intern Med. 1999;159:225-234.
8. Heilbrunn SM, Shah P, Bristow MR, Valentine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483-490.
9. Colucci SW, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia, Pa: WB Saunders Co; 1997:503-517.
10. Fesmire SI, Marcoux LG, Lyyski DS, Sprague MK, Kennedy HL, Eichhorn EJ. Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Am J Cardiol. 1999;84:350-354.
11. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994;90:1765-1773.
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
13. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
14. Packer M, Bristow MR, Cohn JN, et al. The effects of carvedilol on morbidity and mortality in patients with chronic congestive heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
15. Sharpe N. Benefit of beta-blockers for heart failure: proven in 1999. Lancet. 1999;353:1988-1989.
16. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191.
17. US Food and Drug Administration, Center for Drug Evaluation and Research. Toprol-XL. May 1, 2001. Available from: http://www.fda.gov/ cder/foi/label/2001/19962s131bl.pdf. Accessed May 20, 2001.
18. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(suppl 2):S82-S88.
19. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
20. Krum H, Sackner-Bemstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-1506.
21. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2800-2806.
22. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94:2793-2799.
23. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94: 2807-2816.
24. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The US Carvedilol Heart Failure Study Group. J Card Fail. 1997;3:173-179.
25. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation. 1999;99:2645-2651.
26. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551.
27. Smith AJ, Wehner JS, Manley HJ, Richardson AD, Beal J, Bryant PJ. Current role of beta-adrenergic blockers in the treatment of chronic congestive heart failure. Am JHealth Syst Pharm. 2001;58:140-145.
28. American Hospital Formulary Service Drug Information. Bethesda, Md: American Society of Health System Pharmacists; 1999:1405-1407.
29. Physicians' Desk Reference. Entries for metoprolol and carvedilol. Available at: http://physician.pdr.net/physician/static.htm. Accessed March 25, 2001.
30. Katzung BG. Basic and Clinical Pharmacology. Stamford, Conn: Appleton & Lange; 1998:146.
31. Voelker R. New recommendations for CHF [Quick Uptakes]. JAMA. 1999;281:694.
32. National Institutes of Health. NHLBI-VA study finds no heart failure survival increase with beta-blocker [NIH news release]. November 10, 1999. Available at: http://www.nih.gov/news/pr/nov99/nhlbi-10.htm. Accessed January 6, 2001.
33. Witte K, Thackray S, Clark AL, Cooklin M, Cleland JG. Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT, and Heart. Eur JHeart Fail. 2000;2:455-460.